“You may choose to look the other way, but you can never say again that you did not know.”
— William Wilberforce
On Nov. 9, 2020, Pfizer, Inc. announced that the experimental messenger RNA (mRNA) BNT162b2 vaccine for COVID-19 it developed in partnership with Germany’s BioNTech SE had an efficacy rate of 90 percent, based on the results of human clinical trials on the vaccine.1 2 3 This news was followed up a week later with an […]
On Dec. 22, 2020, a patient at Decatur Morgan Hospital in Decatur, Alabama suffered a severe allergic reaction called anaphylaxis just minutes after receiving Pfizer/BioNTech’s experimental messenger RNA (mRNA) BNT162b2 vaccine for COVID-19.1 2 3 In a press release, the Alabama Department of Public Health (ADPH) stated the patient, who reportedly had a history of […]
The chief scientist for the U.S. government’s Operation Warp Speed (OWS) program aimed at facilitating development of COVID-19 vaccines confirmed on Dec. 1, 2020 that 10-15 percent of the volunteers, who participated in clinical trials to test the safety and effectiveness of experimental vaccines developed by Pfizer, Inc. (in partnership with BioNTech SE) and Moderna, […]
On Sept. 8, 2020, nine pharmaceutical companies working on COVID-19 vaccines signed a pledge saying they would not submit their experimental vaccines to the U.S. Food and Drug Administration (FDA) unless they were shown to be both safe and efficacious in the Phase 3 human clinical trials.1 2 3 4 5 The pledge, signed by […]